80 likes | 227 Views
HITF Working Group 2 R&D and the Industrial Base. LWG: innovation Pathway Michael Wilkinson. Issues. Structure disparate industry base, SMEs, varied products NHS - barrier to innovation, no single voice across NHS agencies
E N D
HITF Working Group 2 R&D and the Industrial Base LWG: innovation Pathway Michael Wilkinson
Issues • Structure • disparate industry base, SMEs, varied products • NHS - barrier to innovation, no single voice across NHS agencies • regulatory and ethical environment - makes heatlhcare industry quite different to other sectors • Funding/Investors • disparate and bewildering array of funding sources • lack of understanding by investors • can be small market size for specific products • risk management/proof of concept funding - rapid and correct decisions • Business awareness • appropriate business plans for funding sources being followed (clear market need) • IP ownership • NHS vs academia where jointly developed • value share as new IP brought in during development of product
Risk Gap • Discussion has covered: • funding gap • awareness gap • applicability gap • risk gap • Access to quick funding for early stage proof of concept is an issue • but: • Funding can be available if appropriate business case made • What should HITF define as the issue?
Conclusion - 1 • Innovation routemap • nationally accepted • built on existing guidelines • comprehensive (from market pull, idea generation, to development and sales) • operating on stagegate principles • simple and accessible • must highlight where support services available to make inventors more business ready • must cover: finance, management, technology, regulatory, legal and IP issues
Conclusion - 2 • Brokerage service • enactment of the routemap (support to take inventors through the innovation pathway) • using what exists today (more effective marketing of what’s out there) • regional • local delivery, regional strategy, develop regional clusters, communication route to national picture, regional assessment panels • members of Medical Devices Faraday Federation (Medilinks, Southern Medical Alliance, MediWales, MDIS etc.), NHS Regional Innovation Centres • national • national strategy, mechanism to spread best practice, co-ordination for national and international development bids, co-ordination for national co-operatives and clinical trials • NHS Innovations, Medical Devices Faraday Partnership, ABHI, Medical Futures • mechanism for all bodies to work together efficiently • support to make inventors more investor ready
Regional engage regional stakeholders regional assessment panels identify regional champions broker access to ‘Co-operatives of Excellence’ access to regional clinical trials support for innovation process enable regional innovative procurement regional market intelligence National engage national stakeholders national framework for engagement (innovation pathway) co-ordinate ‘Co-operatives of Excellence) access to national clinical trials national lobbying support scaling up national market intelligence Brokerage 1
Regional support commercialisation including spin-out and spin-in mentoring and exposure to entrepreneurship ensure value of brokerage service National identify national priorities and lobby for new programmes to address these priorities provide good PR/success stories provide exemplar case studies ensure value of brokerage service Brokerage 2